Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: AGR002
MIFTS: 45

Agoraphobia

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Agoraphobia

About this section

MalaCards integrated aliases for Agoraphobia:

Name: Agoraphobia 12 77 56 45 15 17 74
Fear of Open Spaces 12

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:593
MeSH 45 D000379
NCIt 51 C34362
SNOMED-CT 69 70691001
ICD10 34 F40.0 F40.00
UMLS 74 C0001818
Sources

Summaries for Agoraphobia

About this section
Disease Ontology : 12 A phobic disorder involving the specific anxiety about being in a place or situation where escape is difficult or embarrassing or where help may be unavailable.

MalaCards based summary : Agoraphobia, also known as fear of open spaces, is related to depression and social phobia. An important gene associated with Agoraphobia is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Clonazepam and Paroxetine have been mentioned in the context of this disorder. Affiliated tissues include colon, brain and testes, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 77 Agoraphobia is an anxiety disorder characterized by symptoms of anxiety in situations where the person... more...

Sources

Related Diseases for Agoraphobia

About this section

Diseases related to Agoraphobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Related Disease Score Top Affiliating Genes
1 depression 31.2 HTR1A MAOA SLC6A4
2 social phobia 31.0 HTR1A MAOA SLC6A4
3 personality disorder 30.9 HTR1A MAOA SLC6A4
4 panic disorder 30.8 CCKBR HTR1A MAOA PTK7 SLC6A2 SLC6A4
5 obsessive-compulsive disorder 30.8 HTR1A MAOA SLC6A4
6 anxiety 30.7 CCKBR HTR1A MAOA PTK7 SLC6A4
7 atypical depressive disorder 30.2 MAOA SLC6A4
8 alcohol dependence 30.1 HTR1A MAOA SLC6A4
9 disease of mental health 29.9 HTR1A MAOA SLC6A2 SLC6A4
10 phobic disorder 29.9 ASB1 HTR1A MAOA PIR PTK7 RGS2
11 schizophrenia 29.8 HTR1A MAOA SLC6A2 SLC6A4
12 generalized anxiety disorder 29.7 HTR1A MAOA RGS2 SLC6A2 SLC6A4
13 major depressive disorder 29.5 HTR1A MAOA SLC6A2 SLC6A4
14 panic disorder 1 11.4
15 psychosexual disorder 10.3 HTR1A SLC6A4
16 sexual disorder 10.3 HTR1A SLC6A4
17 periodic limb movement disorder 10.3 HTR1A SLC6A4
18 premature ejaculation 10.3 HTR1A SLC6A4
19 avoidant personality disorder 10.3 MAOA SLC6A4
20 alexithymia 10.3 HTR1A SLC6A4
21 intermittent explosive disorder 10.3 HTR1A SLC6A4
22 pathological gambling 10.2 MAOA SLC6A4
23 eating disorder 10.2
24 antisocial personality disorder 10.2 MAOA SLC6A4
25 migraine without aura 10.2 HTR1A SLC6A4
26 paranoid schizophrenia 10.2 MAOA SLC6A4
27 postpartum depression 10.2 MAOA SLC6A4
28 bipolar i disorder 10.2 HTR1A SLC6A4
29 dyspepsia 10.2 HTR1A SLC6A4
30 kleptomania 10.1 HTR1A MAOA SLC6A4
31 schizoid personality disorder 10.1 HTR1A PIR
32 brunner syndrome 10.1 HTR1A MAOA SLC6A4
33 borderline personality disorder 10.1 HTR1A MAOA SLC6A4
34 serotonin syndrome 10.1 HTR1A MAOA SLC6A4
35 endogenous depression 10.1 HTR1A MAOA SLC6A4
36 chronic fatigue syndrome 10.1 HTR1A MAOA SLC6A4
37 phobia, specific 10.1
38 separation anxiety disorder 10.1
39 hyperthyroidism 10.1
40 migraine with or without aura 1 10.1 HTR1A MAOA SLC6A4
41 sudden infant death syndrome 10.1 HTR1A MAOA SLC6A4
42 conduct disorder 10.1 MAOA SLC6A4
43 cocaine abuse 10.1 SLC6A2 SLC6A4
44 dependent personality disorder 10.1 MAOA PIR
45 orthostatic intolerance 10.0
46 hypochondriasis 10.0
47 melancholia 10.0
48 irritable bowel syndrome 10.0
49 substance abuse 10.0 MAOA SLC6A4
50 oppositional defiant disorder 10.0 MAOA SLC6A2 SLC6A4

Graphical network of the top 20 diseases related to Agoraphobia:



Diseases related to Agoraphobia
Sources

Symptoms & Phenotypes for Agoraphobia

About this section

MGI Mouse Phenotypes related to Agoraphobia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 CCKBR GRPR HTR1A MAOA RGS2 SLC6A2
2 cardiovascular system MP:0005385 9.56 CCKBR HTR1A MAOA PTK7 RGS2 SLC6A2
3 nervous system MP:0003631 9.23 CCKBR HTR1A MAOA PTK7 RGS2 SLC6A2
Sources

Drugs & Therapeutics for Agoraphobia

About this section

Drugs for Agoraphobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
2
Paroxetine Approved, Investigational Phase 4,Phase 3 61869-08-7 43815
3
Sertraline Approved Phase 4 79617-96-2 68617
4
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
5
Citalopram Approved Phase 4 59729-33-8 2771
6
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 1 28981-97-7 2118
7
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
8 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
9 GABA Modulators Phase 4,Phase 1
10 Antidepressive Agents Phase 4,Phase 3,Not Applicable
11 Antidepressive Agents, Second-Generation Phase 4,Phase 3
12 GABA Agents Phase 4,Phase 1
13 Serotonin Uptake Inhibitors Phase 4,Phase 3
14 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3
15 Psychotropic Drugs Phase 4,Phase 3,Phase 1
16 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Not Applicable
17 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3
18 Serotonin Agents Phase 4,Phase 3
19 Anticonvulsants Phase 4,Phase 3
20 Dopamine Uptake Inhibitors Phase 4
21 Dopamine Agents Phase 4
22 Lisdexamfetamine Dimesylate Phase 4
23 Central Nervous System Stimulants Phase 4
24 Muscarinic Antagonists Phase 4
25 Cholinergic Antagonists Phase 4
26 Antiparkinson Agents Phase 4
27 Autonomic Agents Phase 4
28 Peripheral Nervous System Agents Phase 4
29 Cholinergic Agents Phase 4
30 Parasympatholytics Phase 4
31 Tranquilizing Agents Phase 4,Phase 1
32 Central Nervous System Depressants Phase 4,Phase 1
33 Hypnotics and Sedatives Phase 4,Phase 1
34 Anti-Anxiety Agents Phase 4,Phase 1,Not Applicable
35 Immunologic Factors Phase 4
36 Immunoglobulins Phase 4
37 Rho(D) Immune Globulin Phase 4
38 Immunoglobulins, Intravenous Phase 4
39 Antibodies Phase 4
40 gamma-Globulins Phase 4
41
Serotonin Investigational, Nutraceutical Phase 4,Phase 3 50-67-9 5202
42
Cycloserine Approved Phase 3,Phase 2 68-41-7 6234 401
43 Serotonin Receptor Agonists Phase 3
44 Anti-Infective Agents Phase 3,Phase 2
45 Antibiotics, Antitubercular Phase 3,Phase 2
46 Antitubercular Agents Phase 3,Phase 2
47 Anti-Infective Agents, Urinary Phase 3,Phase 2
48 Antimetabolites Phase 3,Phase 2
49 Renal Agents Phase 3,Phase 2
50 Anti-Bacterial Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 94)
# Name Status NCT ID Phase Drugs
1 Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine Completed NCT02852577 Phase 4 Clonazepam;Paroxetine
2 A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder Completed NCT00677352 Phase 4 sertraline;Paroxetine
3 Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder Completed NCT00540098 Phase 4 paroxetine + aerobic exercise;Paroxetine + relaxation;Placebo + aerobic exercise;Placebo + relaxation
4 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
5 Treatments for Anxiety: Meditation and Escitalopram Recruiting NCT03522844 Phase 4 Escitalopram
6 A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Active, not recruiting NCT03348618 Phase 4
7 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Not yet recruiting NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
8 A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks Terminated NCT00634790 Phase 4 alprazolam XR
9 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
10 Mechanisms of Panic Disorders Treatment Unknown status NCT01323556 Phase 2, Phase 3
11 Treatment of Panic Disorder: Long Term Strategies Completed NCT00000368 Phase 3 Paroxetine or other medication - algorithm used
12 Comparison of Psychotherapy Programs to Treat Panic Disorder Completed NCT00353470 Phase 3
13 Internet-Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder Completed NCT00845260 Phase 3
14 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
15 Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia Completed NCT00515879 Phase 3 D-cycloserine;Placebo
16 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
17 Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Not yet recruiting NCT03549819 Phase 3 Cannabidiol (CBD) Oil Capsules;Sunflower Lecithin Oil in Capsule
18 Augmentation of Psychotherapy With D-Cycloserine in Agoraphobia Completed NCT01928823 Phase 2 D-Cycloserine
19 Effectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and Agoraphobia Completed NCT00576719 Phase 2
20 Exposure Therapy for Fear of Falling in Older Adults Completed NCT01609322 Phase 2
21 Physical Exercise Versus Cognitive-behavioral Therapy (CBT) for Panic Disorders: A Randomised Controlled Trial Completed NCT01076777 Phase 2
22 Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic Disorder Completed NCT00705380 Phase 2
23 Improve: Integrating Emotion Focused Components Into Psychological Therapy Active, not recruiting NCT02822443 Phase 2
24 The Modular Protocol for Mental Health (MPMH) Enrolling by invitation NCT03143634 Phase 1, Phase 2
25 An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites Completed NCT01330472 Phase 1 Xanax XR tablets 3 mg (sourced from Caugus);Xanax XR tablets 3 mg (sourced from Barceloneta)
26 Virtual Reality for Panic Disorder With Agoraphobia Unknown status NCT03101332 Not Applicable
27 Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia Unknown status NCT00129610 Not Applicable
28 Providing Tools for Effective Care and Treatment of Anxiety Disorders Unknown status NCT02605668 Not Applicable
29 Virtual Reality and Concept of Control in the Treatment of Acrophobia Unknown status NCT02020824 Not Applicable
30 A Randomised Feasibility Trial With Internet Based Self-help Therapy Unknown status NCT02499055 Not Applicable
31 Transdiagnostic Treatment for Early Stage Mental Health Problems in Youth Unknown status NCT02540746 Not Applicable
32 Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma Unknown status NCT02030522 Not Applicable
33 Thought Field Therapy and Cognitive Therapy for Agoraphobia Completed NCT00932919 Not Applicable
34 Physical Activity and Cognitive Behavioural Therapy in Panic Disorder and Agoraphobia Completed NCT01928810 Not Applicable
35 Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for Agoraphobia Completed NCT01446172
36 Mechanisms of Treatment Change in Panic Disorder and Agoraphobia Completed NCT03547180 Not Applicable
37 Virtual Reality Exposure Therapy in Agoraphobic Participants Completed NCT00734370 Not Applicable
38 Cognitive Behavioral Therapy in Panic Disorder Completed NCT00772746
39 Internet-based Exposure Therapy for Panic Disorder Completed NCT03061448 Not Applicable
40 Physical Activity and Cognitive Behavioural Therapy in Panic Disorder Completed NCT01788800 Not Applicable
41 Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia Completed NCT00004367 Not Applicable
42 Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder? Completed NCT00202709 Not Applicable
43 Cognitive Behavior Psychotherapy in Panic Disorder Completed NCT01025908 Not Applicable
44 Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction Completed NCT00004366 Not Applicable
45 Interpretation Modification Program for Social Phobia Completed NCT00684541 Not Applicable
46 Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months Completed NCT00711737
47 Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome Completed NCT02833194
48 Genetic Causes of Panic Disorder Completed NCT00083265
49 Effectiveness of Six Sessions CBT for Adolescents With Emotional Problems in Community Clinics Completed NCT02150265 Not Applicable
50 Transversal Multiaxial Evaluation and 5-year Follow-up of a Cohort of French Gamblers (JEU) Completed NCT01207674 Not Applicable

Search NIH Clinical Center for Agoraphobia

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: agoraphobia

Sources

Genetic Tests for Agoraphobia

About this section
Sources

Anatomical Context for Agoraphobia

About this section

MalaCards organs/tissues related to Agoraphobia:

42
Colon, Brain, Testes, Breast, Thyroid, Cortex, Heart
Sources

Publications for Agoraphobia

About this section

Articles related to Agoraphobia:

(show top 50) (show all 832)
# Title Authors Year
1
The impact of depressive comorbidity on neural plasticity following cognitive-behavioral therapy in panic disorder with agoraphobia. ( 30428445 )
2019
2
Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes. ( 30718541 )
2019
3
A comparison of DSM-5 and DSM-IV agoraphobia in the World Mental Health Surveys. ( 30726581 )
2019
4
Heart rate variability in patients with agoraphobia with or without panic disorder remains stable during CBT but increases following in-vivo exposure. ( 30875662 )
2019
5
Stress hormone response to the DEX-CRH test and its relation to psychotherapy outcome in panic disorder patients with and without agoraphobia. ( 29391399 )
2018
6
Pretreatment Cardiac Vagal Tone Predicts Dropout from and Residual Symptoms after Exposure Therapy in Patients with Panic Disorder and Agoraphobia. ( 29533952 )
2018
7
Running for extinction? Aerobic exercise as an augmentation of exposure therapy in panic disorder with agoraphobia. ( 29539585 )
2018
8
The relationship between impulsivity and panic disorder-agoraphobia: The role of affective temperament. ( 29649673 )
2018
9
Bowel and Bladder Anxiety: An Obsession or a Variant of Agoraphobia? ( 29875534 )
2018
10
Social Support and Symptom Severity Among Patients With Obsessive-Compulsive Disorder or Panic Disorder With Agoraphobia: A Systematic Review. ( 29899808 )
2018
11
Predictors of remission from panic disorder, agoraphobia and specific phobia in outpatients receiving exposure therapy: The importance of positive mental health. ( 29981937 )
2018
12
Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia. ( 30078128 )
2018
13
Integration of EMDR and CBT Techniques in Treatment of Panic Disorder with Agoraphobia - A Case Report. ( 30095822 )
2018
14
Learn to forget: Does post-exposure administration of d-cycloserine enhance fear extinction in agoraphobia? ( 30237105 )
2018
15
Suicidal ideation in primary care patients suffering from panic disorder with or without agoraphobia. ( 30249220 )
2018
16
Effects of Cognitive Behavioral Therapy on Neural Processing of Agoraphobia-Specific Stimuli in Panic Disorder and Agoraphobia. ( 30269148 )
2018
17
Subclinical Agoraphobia Symptoms and Regional Brain Volumes in Non-clinical Subjects: Between Compensation and Resilience? ( 30546323 )
2018
18
Cognitive-behavioural outreach for an adolescent experiencing social anxiety, panic and agoraphobia: A single-case experimental design. ( 30565788 )
2018
19
The role of therapist and patient in-session behavior for treatment outcome in exposure-based cognitive behavioral therapy for panic disorder with agoraphobia. ( 30597535 )
2018
20
The Mobility Inventory for Agoraphobia Avoidance Alone Scale: Factor Structure and Psychometric Properties of Subscales. ( 27449053 )
2018
21
Thought Field Therapy Compared to Cognitive Behavioral Therapy and Wait-List for Agoraphobia: A Randomized, Controlled Study with a 12-Month Follow-up. ( 28676782 )
2017
22
No Effects of D-Cycloserine Enhancement in Exposure With Response Prevention Therapy in Panic Disorder With Agoraphobia: A Double-Blind, Randomized Controlled Trial. ( 28820746 )
2017
23
Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study. ( 28845177 )
2017
24
Neurobiological and clinical effects of fNIRS-controlled rTMS in patients with panic disorder/agoraphobia during cognitive-behavioural therapy. ( 29085773 )
2017
25
Panel Report, IPA Congress Buenos Aires 2017: Claustro-agoraphobia, Bertram Lewin, and the oral triad 6 April 2017. ( 29148571 )
2017
26
Two Novel Cognitive Behavioral Therapy-Based Mobile Apps for Agoraphobia: Randomized Controlled Trial. ( 29175809 )
2017
27
Fear of Fear and Broad Dimensions of Psychopathology over the Course of Cognitive Behavioural Therapy for Panic Disorder with Agoraphobia in Japan. ( 29259145 )
2017
28
Predictors of the application of exposure in vivo in the treatment of agoraphobia in an outpatient clinic: An exploratory approach. ( 26308791 )
2017
29
Predictors of Dropout From Cognitive-Behavioral Group Treatment for Panic Disorder With Agoraphobia: An Exploratory Study. ( 27385412 )
2017
30
Burden and Distress in Caregivers of Patients With Panic Disorder and Agoraphobia. ( 27861457 )
2017
31
Transdiagnostic group CBT vs. standard group CBT for depression, social anxiety disorder and agoraphobia/panic disorder: Study protocol for a pragmatic, multicenter non-inferiority randomized controlled trial. ( 28114915 )
2017
32
Psychoticism in patients with panic disorder with or without comorbid agoraphobia. ( 28345374 )
2017
33
Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder. ( 28418834 )
2017
34
Comorbidity and Suicidality in Patients Diagnosed with Panic Disorder/Agoraphobia and Major Depression. ( 28636577 )
2017
35
Support Vector Machine Analysis of Functional Magnetic Resonance Imaging of Interoception Does Not Reliably Predict Individual Outcomes of Cognitive Behavioral Therapy in Panic Disorder with Agoraphobia. ( 28649205 )
2017
36
Cognitive and Guided Mastery Therapies for Panic Disorder with Agoraphobia: 18-Year Long-Term Outcome and Predictors of Long-Term Change. ( 25452222 )
2016
37
Panic disorder and agoraphobia: A direct comparison of their multivariate comorbidity patterns. ( 26480214 )
2016
38
Agoraphobia With and Without Panic Disorder: A 20-Year Follow-up of Integrated Exposure and Psychodynamic Therapy. ( 26588081 )
2016
39
SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL. ( 26663632 )
2016
40
Facing the fear--clinical and neural effects of cognitive behavioural and pharmacotherapy in panic disorder with agoraphobia. ( 26837851 )
2016
41
Panic disorder with agoraphobia from a behavioral neuroscience perspective: Applying the research principles formulated by the Research Domain Criteria (RDoC) initiative. ( 26877119 )
2016
42
Agoraphobia Related to Unassertiveness in Panic Disorder. ( 26915016 )
2016
43
Insomnia Symptoms Following Treatment for Comorbid Panic Disorder With Agoraphobia and Generalized Anxiety Disorder. ( 27019339 )
2016
44
Threat expectancy bias and treatment outcome in patients with panic disorder and agoraphobia. ( 27061246 )
2016
45
Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. ( 27071857 )
2016
46
Cognitive models for panic disorder with agoraphobia: A study of disaggregated within-person effects. ( 27123977 )
2016
47
The role of treatment delivery factors in exposure-based cognitive behavioral therapy for panic disorder with agoraphobia. ( 27235836 )
2016
48
A discussion of various aspects of panic disorder depending on presence or absence of agoraphobia. ( 27423353 )
2016
49
Platzschwindel, agoraphobia and their influence on theories of anxiety at the end of the nineteenth century: theories of the role of biology and 'representations' (Vorstellungen). ( 27450798 )
2016
50
A Comparison of Psychoanalytic Therapy and Cognitive Behavioral Therapy for Anxiety (Panic/Agoraphobia) and Personality Disorders (APD Study): Presentation of the RCT Study Design. ( 27594602 )
2016
Sources

Variations for Agoraphobia

About this section
Sources

Expression for Agoraphobia

About this section
Search GEO for disease gene expression data for Agoraphobia.
Sources

Pathways for Agoraphobia

About this section

Pathways related to Agoraphobia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.65 HTR1A MAOA SLC6A4
2
Serotonergic synapse 38
11.39 HTR1A MAOA SLC6A4
3
Monoamine Transport 1
Show member pathways
 10.77 MAOA SLC6A2 SLC6A4
4
Neurotransmitter Clearance In The Synaptic Cleft 67
Show member pathways
 10.75 MAOA SLC6A4
5
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 62
10.25 HTR1A MAOA SLC6A4
Sources

GO Terms for Agoraphobia

About this section

Cellular components related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.35 GRPR HTR1A PTK7 SLC6A2 SLC6A4
2 neuron projection GO:0043005 8.92 RGS2 SLC6A2 SLC6A4 STMN1

Biological processes related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.37 CCKBR GRPR
2 brain development GO:0007420 9.33 RGS2 SLC6A4 STMN1
3 social behavior GO:0035176 9.32 GRPR SLC6A4
4 neurotransmitter transport GO:0006836 9.26 SLC6A2 SLC6A4
5 vasoconstriction GO:0042310 8.96 HTR1A SLC6A4
6 monoamine transport GO:0015844 8.62 SLC6A2 SLC6A4

Molecular functions related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 beta-tubulin binding GO:0048487 9.26 RGS2 SLC6A2
2 neurotransmitter:sodium symporter activity GO:0005328 9.16 SLC6A2 SLC6A4
3 serotonin binding GO:0051378 8.96 HTR1A SLC6A4
4 monoamine transmembrane transporter activity GO:0008504 8.62 SLC6A2 SLC6A4
Sources

Sources for Agoraphobia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....